{"id":"W4361204681","doi":"10.3390/cancers15072015","title":"Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer","year":2023,"lang":"en","type":"review","venue":"Cancers","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Fulvestrant; Exemestane; Metastatic breast cancer; Medicine; Everolimus; Oncology; Internal medicine; Palbociclib; Breast cancer; Cancer; Estrogen receptor; Clinical trial; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001323636,0.0006866051,0.001707386,0.0001877526,0.0001970436,0.00003787696,0.0001344808,0.0001256786,0.0001011671],"category_scores_gemma":[0.00003893119,0.0003941697,0.0005244359,0.0004666543,0.0003370142,0.00008785794,0.00006314897,0.0002841235,0.00002070385],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00435869,"about_ca_system_score_gemma":0.001234988,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005088685,"about_ca_topic_score_gemma":0.0001111313,"domain_scores_codex":[0.997874,0.00006982713,0.0005673759,0.0007261966,0.0001846981,0.0005779613],"domain_scores_gemma":[0.9983712,0.0004852316,0.0003748756,0.0004129104,0.0001665372,0.000189196],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005688252,0.00004760286,0.00000423598,0.004456734,0.002956056,0.00002132178,0.0003589764,0.00006281574,0.00008182565,0.00007548831,0.000479793,0.9908863],"study_design_scores_gemma":[0.002221581,0.00053531,0.00004627003,0.01286477,0.004594538,0.0003418791,0.0003808242,0.00003622735,0.00002056119,0.00005327185,0.9783674,0.000537323],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00008299037,0.9839041,0.0003307209,0.000887413,0.0005504254,0.003839408,0.01027162,0.0001152648,0.00001806432],"genre_scores_gemma":[0.00007864143,0.9828476,0.001572782,0.0002312897,0.001220414,0.01211197,0.0005226255,0.000162587,0.001252053],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.990349,"threshold_uncertainty_score":0.999851,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09731471734959683,"score_gpt":0.3832936032639684,"score_spread":0.2859788859143715,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}